一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Pumitamig；Imzokitug；Pemetrexed；Cisplatin；Carboplatin；Paclitaxel；Infliximab；Vedolizumab，当前状态为招募中。登记地点显示中国北京、福州、武汉、南京等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pumitamig；Imzokitug；Pemetrexed；Cisplatin；Carboplatin；Paclitaxel；Infliximab；Vedolizumab · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0038 · 北京
- Local Institution - 0138 · 福州
- Local Institution - 0050 · 武汉
- Local Institution - 0147 · 南京
- Local Institution - 0140 · 上海
- Local Institution - 0169 · 上海
- Local Institution - 0144 · 成都
- Local Institution - 0137 · 杭州
公开的入选条件
- * Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition.
- * Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- * Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site.
- * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- * Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Exclusion Criteria
- * Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.
- * Participants must not have prior treatment with immuno-oncology therapies.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07680764；登记信息更新于 2026-09-16。